Therapies to Accelerate Resolution of Acute Lung Inflammation

Case ID:
C13113
Acute respiratory distress syndrome (ARDS) is a devastating inflammatory lung disease for which there are no effective targeted therapies.  In experimental models of acute lung inflammation and injury, regulatory T cells (Tregs) orchestrate a pro-repair program; Tregs themselves are highly dependent on epigenetic mechanisms such as DNA hypomethylation.  We found that systemically administering an inhibitor of DNA methylation (5-aza-2'-deoxycytidine [aka AZA and decitabine]) accelerates resolution of established lipopolysaccharide-induced lung injury in mice and requires Tregs for its pro-resolution effect.  Moreover, AZA treatment of isolated Tregs increases their pro-repair function and allows a small number of Tregs to promote resolution of injury upon adoptive transfer to an injured animal.
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
COMPOSITIONS AND METHODS TO ACCELERATE RESOLUTION OF ACUTE LUNG INFLAMMATION PCT: Patent Cooperation Treaty United States 15/542,380 10,905,706 7/7/2017 2/2/2021 3/9/2036 Granted
Compositions and Methods to Accelerate Resolution of Acute Lung Inflammation DIV: Divisional United States 17/139,665   12/31/2020     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum